Literature DB >> 21790998

A reinvestigation of the lipopolysaccharide structure of Helicobacter pylori strain Sydney (SS1).

Eleonora Altman1, Vandana Chandan, Jianjun Li, Evgeny Vinogradov.   

Abstract

In this study, we describe a reinvestigation of the lipopolysaccharide (LPS) structure of Helicobacter pylori strain Sydney (SS1) based on the NMR analysis of oligosaccharides obtained through the use of various degradations of the LPS as well as capillary electrophoresis-MS data. The results of the analysis indicated that the core region of a major H. pylori SS1 LPS glycoform consists of a backbone core oligosaccharide substituted at the D-glycero-D-manno-heptose (DD-Hep) residue by a linear chain composed of a trisaccharide fragment α-ddHep-3-α-L-Fuc-3-β-GlcNAc, as previously demonstrated for H. pylori strain 26695, further elongated by consecutively added α-Glc and β-Gal residues, and terminating in a novel linear chain consisting of 1,2-linked β-ribofuranosyl residues, where the last β-ribofuranosyl residue provides a point of attachment for the O-chain polysaccharide: [Formula: see text] where [2-β-Ribf-](n) is a short (three to five residues) oligomer of 1,2-linked β-ribofuranose (riban), and PS is a polysaccharide chain consisting of N-acetyllactosamine, substituted with α-Fuc to form Lewis (Le)-type structures. In addition to the previously identified LacNAc, Le(y) and Le(x) components, the O-chain polysaccharide of H. pylori SS1 LPS was found to contain a novel LacNAc unit carrying a phosphoethanolamine substituent at the O-6 position of β-GlcNAc residues.
© 2011 National Research Council Canada. Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21790998     DOI: 10.1111/j.1742-4658.2011.08270.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

1.  The potential of dextran-based glycoconjugates for development of Helicobacter pylori vaccine.

Authors:  Eleonora Altman; Vandana Chandan; Blair Harrison
Journal:  Glycoconj J       Date:  2013-08-30       Impact factor: 2.916

2.  Recruiting the host's immune system to target Helicobacter pylori's surface glycans.

Authors:  Pornchai Kaewsapsak; Onyinyechi Esonu; Danielle H Dube
Journal:  Chembiochem       Date:  2013-03-19       Impact factor: 3.164

3.  Comparison of lipopolysaccharides composition of two different strains of Helicobacter pylori.

Authors:  Kristy Leker; Ivonne Lozano-Pope; Keya Bandyopadhyay; Biswa P Choudhury; Marygorret Obonyo
Journal:  BMC Microbiol       Date:  2017-12-04       Impact factor: 3.605

4.  TIFA Signaling in Gastric Epithelial Cells Initiates the cag Type 4 Secretion System-Dependent Innate Immune Response to Helicobacter pylori Infection.

Authors:  Alevtina Gall; Ryan G Gaudet; Scott D Gray-Owen; Nina R Salama
Journal:  mBio       Date:  2017-08-15       Impact factor: 7.867

5.  The redefinition of Helicobacter pylori lipopolysaccharide O-antigen and core-oligosaccharide domains.

Authors:  Hong Li; Tiandi Yang; Tingting Liao; Aleksandra W Debowski; Hans-Olof Nilsson; Alma Fulurija; Stuart M Haslam; Barbara Mulloy; Anne Dell; Keith A Stubbs; Barry J Marshall; Mohammed Benghezal
Journal:  PLoS Pathog       Date:  2017-03-17       Impact factor: 6.823

6.  East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide.

Authors:  Hong Li; Michael Marceau; Tiandi Yang; Tingting Liao; Xiaoqiong Tang; Renwei Hu; Yan Xie; Hong Tang; Alfred Tay; Ying Shi; Yalin Shen; Tiankuo Yang; Xuenan Pi; Binit Lamichhane; Yong Luo; Aleksandra W Debowski; Hans-Olof Nilsson; Stuart M Haslam; Barbara Mulloy; Anne Dell; Keith A Stubbs; Barry J Marshall; Mohammed Benghezal
Journal:  PLoS Genet       Date:  2019-11-20       Impact factor: 5.917

Review 7.  Lipopolysaccharide Structural Differences between Western and Asian Helicobacter pylori Strains.

Authors:  Hong Li; Hong Tang; Aleksandra W Debowski; Keith A Stubbs; Barry J Marshall; Mohammed Benghezal
Journal:  Toxins (Basel)       Date:  2018-09-08       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.